| Autor: |
F., Yusupov A., Kh., Karimova M., A., Djamalova S., K., Makhkamova D., I., Abdullaeva S., A., Zakirkhodjaeva M., A., Khodjaeva Z., A., Rakhimova D. |
| Předmět: |
|
| Zdroj: |
Journal of Ophthalmology (Ukraine) / Oftalʹmologičeskij Žurnal; 2024, Issue 3, p28-32, 7p |
| Abstrakt: |
Aim. To evaluate the short-term efficacy of using a monoclonal antibody fragment (Brolucizumab) for treating neovascular age-related macular degeneration, depending on the morphometric parameters of the retina. Methods. This study included 48 patients (60 eyes) diagnosed with neovascular age-related macular degeneration (nAMD). The observation period was 6 months. Brolucizumab was administered intravitreally at a dose of 6 mg (0.05 ml, 120 mg/ml) once a month consistently for 3-4 months. Depending on the morphometric parameters, the retina patients were divided into three main groups. Results. A pronounced clinical and morphological response was achieved after the first injection of Brolucizumab, and positive dynamics were observed throughout the entire observation period. Conclusions. The use of the drug Brolucizumab significantly improves the visual functions of patients with neovascular AMD, as well as the morphological state of the retina in shortterm follow-up, regardless of the initial morphometric characteristics of the retina, which allows not only to maintain but also to improve visual acuity and prevent blindness and visual disability in patients. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
